meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
sintilimab based treatment
sintilimab
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab plus bevacizumab
title
Standard of Care (SoC)
title
IMbrave050, 2023 NCT04102098 mHCC - (neo)adjuvant (NA) 334/334
Pathology:
mHCC - (neo)adjuvant (NA);
mHCC - (neo)adjuvant (NA)
IMbrave050, 2023
atezolizumab plus bevacizumab
1
T1
Standard of Care (SoC)
0
T0